✅ No sanctions, screening, insolvency or control red flags found in the public sources we cover. (Absence of a flag is not a guarantee — see methodology.)
TRANSGENE
5599 · RC 317540581 · Active since 1979
Overview
TRANSGENE is a 5599 registered , France, since 1979. The company operates in the 7211 sector. With reported revenue of 6.1M EUR in 2024. Its TraceComp score of 85 (A) indicates solid fundamentals and low apparent risk. With 47 years of operations, the company has an established track record in its market.
Company Information
- Registration Number
- 317540581
- Legal Form
- 5599
- Registered
- 1979-01-01
Financial Profile
Latest filed accounts: FY 2024
Multi-year financials & ratios
5 years of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Officers & Management
13 officers/directors on file — names, roles, appointment & resignation dates.
| Name | Role | Status |
|---|---|---|
| CHRISTOPHE ANCEL | role 70 | Current |
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Research Output
Active research organization. 1,641 publications · 234,304 citations · h-index 222 in the global scholarly record (OpenAlex — 82.9M papers). Top fields by publication volume: Biochemistry, Genetics and Molecular Biology (65%) · Immunology and Microbiology (22%) · Medicine (13%).
See full research profile — top researchers & publications →
Source: OpenAlex (CC0). Objective publication & citation counts.
Patent Portfolio
Active patent holder. 4 patents · 2 active · 4 granted in the USPTO/EPO record.
See full patent portfolio — most-cited inventions & inventors →
Source: USPTO / EPO open patent data. Objective bibliographic counts.
Risk Signals
No adverse legal events have been recorded for this company.
- Revenue up 95% year-on-year
- Altman Z-Score in the distress zone — elevated insolvency risk on the model
Data Sources & Freshness
Data sourced from: bulk register.